

Supplemental Table 1. Summary of Studies Included in the Pooled Safety Analyses for Cariprazine in Schizophrenia				
Cariprazine Studies				
	RGH-MD-03	RGH-MD-16	RGH-MD-04	RGH-MD-05
Location	37 centers (US)	65 centers (US, India, Russia, Ukraine, Malaysia)	58 centers (US, Romania, Russia, Ukraine)	41 centers (US, Colombia, India, South Africa)
Design	Multicenter, randomized, double-blind, placebo-controlled, parallel-group	Multicenter, randomized, double-blind, placebo- and active-controlled, parallel-group	Multicenter, randomized, double-blind, placebo- and active-controlled, parallel-group	Multicenter, randomized, double-blind, placebo-controlled, parallel-group
Study duration	11 weeks: a no-drug screening period of up to 7 days, 6-week double-blind treatment, 4-week safety follow-up	9 weeks: a no-drug screening period of up to 7 days, 6-week double-blind treatment, 2-week safety follow-up	9 weeks: a no-drug screening period of up to 7 days, 6-week double-blind treatment, 2-week safety follow-up	9 weeks: a no-drug screening period of up to 7 days, 6-week double-blind treatment, 2-week safety follow-up
Patient population	Acute exacerbation of schizophrenia	Acute exacerbation of schizophrenia	Acute exacerbation of schizophrenia	Acute exacerbation of schizophrenia
Hospitalization	During screening	During screening and for a minimum of 4 weeks during double-blind treatment	During screening and for a minimum of 4 weeks during double-blind treatment	During screening and for a minimum of 4 weeks during

				double-blind treatment
Dosing	Flexible-dose	Fixed-dose	Fixed-dose	Fixed/flexible-dose
Treatment arms (number of patients randomized per group)	Placebo (130) Cariprazine 1.5-4.5 mg/d (128) 6-12 mg/d (134)	Placebo (151) Cariprazine: 1.5 mg/d (145) 3.0 mg/d (147) 4.5 mg/d (148) Risperidone 4.0 mg/d (141)	Placebo (153) Cariprazine: 3.0 mg/d (155) 6.0 mg/d (157) Aripiprazole 10 mg/d (152)	Placebo (147) Cariprazine: 3-6 mg/d (151) 6-9 mg/d (148)